SAB Biotherapeutics registers resale of up to 250M shares by selling stockholders; company gets no proceeds

Filed August 21, 2026 · ~1 min read

Key Changes

• high

  The prospectus registers resale of up to 250,000,000 shares of common stock by selling stockholders, issuable upon conversion of Series B preferred stock and exercise of warrants.

  The Offering verify on EDGAR →
• high

  The company will not receive any proceeds from these resales; all proceeds go to the selling stockholders.

  The Offering verify on EDGAR →
• high

  The 250M shares consist of 100M from Series B preferred conversion, 100M from enrollment date warrants, and 50M from release date warrants.

  The Offering verify on EDGAR →